{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:26:57Z","timestamp":1784298417498,"version":"3.55.0"},"reference-count":185,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institutes of Health (NIH) and National Cancer Institute (NCI)","award":["R01-CA087546"],"award-info":[{"award-number":["R01-CA087546"]}]},{"name":"National Institutes of Health (NIH) and National Cancer Institute (NCI)","award":["R01-CA190722"],"award-info":[{"award-number":["R01-CA190722"]}]},{"name":"National Institutes of Health (NIH) and National Cancer Institute (NCI)","award":["R01-CA062275"],"award-info":[{"award-number":["R01-CA062275"]}]},{"name":"National Institutes of Health (NIH) and National Cancer Institute (NCI)","award":["R01-078480"],"award-info":[{"award-number":["R01-078480"]}]},{"name":"National Institutes of Health (NIH) and National Cancer Institute (NCI)","award":["R03 CA180550"],"award-info":[{"award-number":["R03 CA180550"]}]},{"name":"University of Texas MD Anderson CCSG","award":["P30 CA16672"],"award-info":[{"award-number":["P30 CA16672"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1053\/j.seminoncol.2015.09.002","type":"journal-article","created":{"date-parts":[[2015,9,26]],"date-time":"2015-09-26T05:25:34Z","timestamp":1443245134000},"page":"49-64","source":"Crossref","is-referenced-by-count":143,"title":["Retinoids and rexinoids in cancer prevention: from laboratory to clinic"],"prefix":"10.1053","volume":"43","author":[{"given":"Iv\u00e1n P.","family":"Uray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Dmitrovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Powel H.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"40","key":"10.1053\/j.seminoncol.2015.09.002_bib1","first-page":"2033","article-title":"[Vitamin A therapy of carcinomata]","volume":"94","author":"Ries","year":"1952","journal-title":"Munch Med Wochenschrift"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib2","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/0002-9378(50)90302-4","article-title":"Vitamin A therapy in the treatment of vulvar leucoplakia","volume":"59","author":"Hyams","year":"1950","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.002_bib3","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0024-3205(73)90084-2","article-title":"Inhibitory action of vitamin A on a murine sarcoma","volume":"13","author":"Seifter","year":"1973","journal-title":"Life Sci"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.002_bib4","first-page":"299","article-title":"Vitamin A AND VITAMIN A acid in the prophylaxis and therapy of epithelial tumours. Internationale Zeitschrift fur Vitaminforschung. International journal of vitamin research","volume":"40","author":"Bollag","year":"1970","journal-title":"J Int Vitamin"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib5","first-page":"1332","article-title":"Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids)","volume":"35","author":"Sporn","year":"1976","journal-title":"Fed Proc"},{"issue":"12","key":"10.1053\/j.seminoncol.2015.09.002_bib6","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJM199009203231205","article-title":"Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck","volume":"323","author":"Hong","year":"1990","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.002_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM199301073280103","article-title":"Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis","volume":"328","author":"Lippman","year":"1993","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1053\/j.seminoncol.2015.09.002_bib8","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198612113152401","article-title":"13-cis-retinoic acid in the treatment of oral leukoplakia","volume":"315","author":"Hong","year":"1986","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib9","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1096\/fj.09-150995","article-title":"ISX is a retinoic acid-sensitive gatekeeper that controls intestinal beta,beta-carotene absorption and vitamin A production","volume":"24","author":"Lobo","year":"2010","journal-title":"FASEB J"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.002_bib10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1053\/meta.2003.50082","article-title":"Portugal H, Lairon D, Borel P. Amounts and types of fatty acids in meals affect the pattern of retinoids secreted in human chylomicrons after a high-dose preformed vitamin A intake","volume":"52","author":"Sauvant","year":"2003","journal-title":"Metabolism"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.002_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1194\/jlr.M043844","article-title":"Genetic dissection of retinoid esterification and accumulation in the liver and adipose tissue","volume":"55","author":"Wongsiriroj","year":"2014","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.002_bib12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1165\/ajrcmb.26.1.4575","article-title":"Alveolar proliferation, retinoid synthesizing enzymes, and endogenous retinoids in the postnatal mouse lung. Different roles for Aldh-1 and Raldh-2","volume":"26","author":"Hind","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib13","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/nm.2757","article-title":"Retinaldehyde dehydrogenase 1 regulates a thermogenic program in white adipose tissue","volume":"18","author":"Kiefer","year":"2012","journal-title":"Nat Med"},{"key":"10.1053\/j.seminoncol.2015.09.002_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-386041-5.00001-7","article-title":"The membrane receptor for plasma retinol-binding protein, a new type of cell-surface receptor","volume":"288","author":"Sun","year":"2011","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1053\/j.seminoncol.2015.09.002_bib15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev-pathol-011110-130303","article-title":"retinoic acid receptors, and cancer","volume":"6","author":"Tang","year":"2011","journal-title":"Ann Rev Pathol"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0092-8674(92)90479-V","article-title":"9-cis retinoic acid is a high affinity ligand for the retinoid X receptor","volume":"68","author":"Heyman","year":"1992","journal-title":"Cell"},{"issue":"6389","key":"10.1053\/j.seminoncol.2015.09.002_bib17","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/358771a0","article-title":"Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors","volume":"358","author":"Kliewer","year":"1992","journal-title":"Nature"},{"issue":"5499","key":"10.1053\/j.seminoncol.2015.09.002_bib18","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1126\/science.290.5499.2140","article-title":"Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain","volume":"290","author":"de Urquiza","year":"2000","journal-title":"Science"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.002_bib19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1074\/mcp.M400003-MCP200","article-title":"Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor alpha ligand-binding domain","volume":"3","author":"Lengqvist","year":"2004","journal-title":"Mol Cell Proteomics"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.002_bib20","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1124\/pr.58.4.4","article-title":"International Union of Pharmacology. LX. Retinoic acid receptors","volume":"58","author":"Germain","year":"2006","journal-title":"Pharmacol Rev"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.tcb.2007.04.003","article-title":"Protein kinases and the proteasome join in the combinatorial control of transcription by nuclear retinoic acid receptors","volume":"17","author":"Bour","year":"2007","journal-title":"Trends Cell Biol"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.002_bib22","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nrm1680","article-title":"Controlling nuclear receptors: the circular logic of cofactor cycles","volume":"6","author":"Perissi","year":"2005","journal-title":"Nat Rev"},{"issue":"14","key":"10.1053\/j.seminoncol.2015.09.002_bib23","first-page":"3518","article-title":"Overexpression of retinoic acid receptor beta in head and neck squamous cell carcinoma cells increases their sensitivity to retinoid-induced suppression of squamous differentiation by retinoids","volume":"59","author":"Wan","year":"1999","journal-title":"Cancer Res"},{"issue":"21","key":"10.1053\/j.seminoncol.2015.09.002_bib24","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199505253322103","article-title":"Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin","volume":"332","author":"Lotan","year":"1995","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.002_bib25","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/sj.bjc.6602995","article-title":"A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours","volume":"94","author":"Yen","year":"2006","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1053\/j.seminoncol.2015.09.002_bib26","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1371\/journal.pbio.0060227","article-title":"Identification of COUP-TFII orphan nuclear receptor as a retinoic acid-activated receptor","volume":"6","author":"Kruse","year":"2008","journal-title":"PLoS Biol"},{"issue":"10","key":"10.1053\/j.seminoncol.2015.09.002_bib27","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nsb979","article-title":"All-trans retinoic acid is a ligand for the orphan nuclear receptor ROR beta","volume":"10","author":"Stehlin-Gaon","year":"2003","journal-title":"Nat Struct Biol"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.002_bib28","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1128\/MCB.23.8.2844-2858.2003","article-title":"Isotype-restricted corepressor recruitment: a constitutively closed helix 12 conformation in retinoic acid receptors beta and gamma interferes with corepressor recruitment and prevents transcriptional repression","volume":"23","author":"Farboud","year":"2003","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.002_bib29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1478-1336-2-4","article-title":"Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: a novel mechanism for reduced hepatic gene expression in inflammation","volume":"2","author":"Ghose","year":"2004","journal-title":"Nucl Receptor"},{"issue":"9","key":"10.1053\/j.seminoncol.2015.09.002_bib30","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1128\/MCB.24.9.3972-3982.2004","article-title":"Altered localization of retinoid X receptor alpha coincides with loss of retinoid responsiveness in human breast cancer MDA-MB-231 cells","volume":"24","author":"Tanaka","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib31","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1053\/jhep.2002.31164","article-title":"Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma","volume":"35","author":"Adachi","year":"2002","journal-title":"Hepatology"},{"issue":"19","key":"10.1053\/j.seminoncol.2015.09.002_bib32","doi-asserted-by":"crossref","first-page":"8754","DOI":"10.1158\/0008-5472.CAN-04-3569","article-title":"Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor","volume":"65","author":"Altucci","year":"2005","journal-title":"Cancer Res"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.002_bib33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrm1009","article-title":"Nongenomic actions of steroid hormones","volume":"4","author":"Losel","year":"2003","journal-title":"Nat Rev"},{"issue":"15","key":"10.1053\/j.seminoncol.2015.09.002_bib34","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1128\/MCB.00505-12","article-title":"Cross talk between signaling and vitamin A transport by the retinol-binding protein receptor STRA6","volume":"32","author":"Berry","year":"2012","journal-title":"Mol Cell Biol"},{"issue":"10","key":"10.1053\/j.seminoncol.2015.09.002_bib35","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1210\/me.2007-0062","article-title":"Rapid, nongenomic actions of retinoic acid on phosphatidylinositol-3-kinase signaling pathway mediated by the retinoic acid receptor","volume":"21","author":"Masia","year":"2007","journal-title":"Mol Endocrinol"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib36","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1091\/mbc.E05-06-0519","article-title":"Nonclassical action of retinoic acid on the activation of the cAMP response element-binding protein in normal human bronchial epithelial cells","volume":"17","author":"Aggarwal","year":"2006","journal-title":"Mol Biol Cell"},{"issue":"28","key":"10.1053\/j.seminoncol.2015.09.002_bib37","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1038\/onc.2011.499","article-title":"A retinoic acid receptor RARalpha pool present in membrane lipid rafts forms complexes with G protein alphaQ to activate p38MAPK","volume":"31","author":"Piskunov","year":"2012","journal-title":"Oncogene"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.002_bib38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/emboj.2008.256","article-title":"A coordinated phosphorylation cascade initiated by p38MAPK\/MSK1 directs RARalpha to target promoters","volume":"28","author":"Bruck","year":"2009","journal-title":"EMBO J"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib39","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1074\/jbc.M007431200","article-title":"Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid","volume":"276","author":"Alsayed","year":"2001","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.002_bib40","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1128\/MCB.01352-06","article-title":"CSK controls retinoic acid receptor (RAR) signaling: a RAR-c-SRC signaling axis is required for neuritogenic differentiation","volume":"27","author":"Dey","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"30","key":"10.1053\/j.seminoncol.2015.09.002_bib41","doi-asserted-by":"crossref","first-page":"20841","DOI":"10.1074\/jbc.M802314200","article-title":"The nuclear transcription factor RARalpha associates with neuronal RNA granules and suppresses translation","volume":"283","author":"Chen","year":"2008","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.002_bib42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM197902153000701","article-title":"Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid","volume":"300","author":"Peck","year":"1979","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1346-8138.2010.00962.x","article-title":"Clinical effect of tocoretinate on lichen and macular amyloidosis","volume":"38","author":"Terao","year":"2011","journal-title":"J Dermatol"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib44","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/jid.2011.483","article-title":"Tretinoin and the prevention of keratinocyte carcinoma (Basal and squamous cell carcinoma of the skin): a Veterans Affairs randomized chemoprevention trial","volume":"132","author":"Weinstock","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.002_bib45","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1396-0296.2003.01644.x","article-title":"Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma","volume":"16","author":"Zhang","year":"2003","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.002_bib46","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1378\/chest.130.5.1334","article-title":"Feasibility of retinoids for the treatment of emphysema study","volume":"130","author":"Roth","year":"2006","journal-title":"Chest"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.002_bib47","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/thx.2008.105437","article-title":"Retinoid induction of alveolar regeneration: from mice to man?","volume":"64","author":"Hind","year":"2009","journal-title":"Thorax"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib48","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1183\/09031936.00161911","article-title":"Randomised controlled trial for emphysema with a selective agonist of the gamma-type retinoic acid receptor","volume":"40","author":"Stolk","year":"2012","journal-title":"Eur Respir J"},{"issue":"32","key":"10.1053\/j.seminoncol.2015.09.002_bib49","doi-asserted-by":"crossref","first-page":"13112","DOI":"10.1073\/pnas.1210833109","article-title":"Liver X receptor beta protects dopaminergic neurons in a mouse model of Parkinson disease","volume":"109","author":"Dai","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"48","key":"10.1053\/j.seminoncol.2015.09.002_bib50","doi-asserted-by":"crossref","first-page":"17321","DOI":"10.1523\/JNEUROSCI.1569-12.2012","article-title":"PPARgamma\/RXRalpha-induced and CD36-mediated microglial amyloid-beta phagocytosis results in cognitive improvement in amyloid precursor protein\/presenilin 1 mice","volume":"32","author":"Yamanaka","year":"2012","journal-title":"J Neurosci"},{"issue":"6075","key":"10.1053\/j.seminoncol.2015.09.002_bib51","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1126\/science.1217697","article-title":"ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models","volume":"335","author":"Cramer","year":"2012","journal-title":"Science"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.002_bib52","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1021\/cn400100f","article-title":"Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson\u05f3s disease","volume":"4","author":"McFarland","year":"2013","journal-title":"ACS Chem Neurosci"},{"issue":"38","key":"10.1053\/j.seminoncol.2015.09.002_bib53","doi-asserted-by":"crossref","first-page":"35118","DOI":"10.1074\/jbc.M201707200","article-title":"Defining requirements for heterodimerization between the retinoid X receptor and the orphan nuclear receptor Nurr1","volume":"277","author":"Aarnisalo","year":"2002","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib54","first-page":"700","article-title":"Flexor MA, Lanotte M, Chabot GG. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites","volume":"61","author":"Idres","year":"2001","journal-title":"Cancer Res"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.002_bib55","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1128\/MCB.15.7.3540","article-title":"Activation of retinoid X receptors induces apoptosis in HL-60 cell lines","volume":"15","author":"Nagy","year":"1995","journal-title":"Mol Cell Biol"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib56","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1073\/pnas.052011299","article-title":"UBE1L is a retinoid target that triggers PML\/RARalpha degradation and apoptosis in acute promyelocytic leukemia","volume":"99","author":"Kitareewan","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"10.1053\/j.seminoncol.2015.09.002_bib57","doi-asserted-by":"crossref","first-page":"9875","DOI":"10.1158\/0008-5472.CAN-10-1100","article-title":"Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML\/RARalpha and inhibits the growth of acute promyelocytic leukemia","volume":"70","author":"Guo","year":"2010","journal-title":"Cancer Res"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib58","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/MOH.0b013e3283257aee","article-title":"Differentiation therapy of acute myeloid leukemia: past, present and future","volume":"16","author":"Petrie","year":"2009","journal-title":"Curr Opin Hematol"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.002_bib59","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.leukres.2013.03.001","article-title":"All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129","volume":"37","author":"Douer","year":"2013","journal-title":"Leuk Res"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.002_bib60","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1182\/blood.V91.11.4300","article-title":"Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells","volume":"91","author":"Gianni","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.002_bib61","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-0-387-69259-3_13","article-title":"Acute promyelocytic leukemia: a paradigm for differentiation therapy","volume":"145","author":"Grimwade","year":"2010","journal-title":"Cancer Treat Res"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib63","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00128071-200102020-00004","article-title":"International Panretin Gel KSSG. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi\u05f3s sarcoma","volume":"2","author":"Bodsworth","year":"2001","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.002_bib64","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00002030-200202150-00014","article-title":"Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi\u05f3s sarcoma","volume":"16","author":"Miles","year":"2002","journal-title":"Aids"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.002_bib65","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2004.06.155","article-title":"Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)","volume":"22","author":"Atzpodien","year":"2004","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1053\/j.seminoncol.2015.09.002_bib66","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2006.05.9873","article-title":"Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma","volume":"25","author":"Brewster","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.002_bib67","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/1097-0142(20010815)92:4<814::AID-CNCR1387>3.0.CO;2-8","article-title":"Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I-II study","volume":"92","author":"Recchia","year":"2001","journal-title":"Cancer"},{"issue":"9","key":"10.1053\/j.seminoncol.2015.09.002_bib68","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/cncr.22596","article-title":"Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma","volume":"109","author":"Straus","year":"2007","journal-title":"Cancer"},{"issue":"13","key":"10.1053\/j.seminoncol.2015.09.002_bib69","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1517\/14656566.2013.810718","article-title":"Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature","volume":"14","author":"Quereux","year":"2013","journal-title":"Exp Opin Pharmacother"},{"issue":"1-2","key":"10.1053\/j.seminoncol.2015.09.002_bib70","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0304-3835(03)00108-3","article-title":"Retinoid therapy of high-risk neuroblastoma","volume":"197","author":"Reynolds","year":"2003","journal-title":"Cancer Lett"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.002_bib71","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2007.13.8925","article-title":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children\u05f3s Oncology Group study","volume":"27","author":"Matthay","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.002_bib72","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/pbc.24643","article-title":"Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed\/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium","volume":"60","author":"Maurer","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.002_bib73","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s002800050666","article-title":"Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial","volume":"40","author":"Sutton","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.002_bib74","first-page":"991","article-title":"Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients","volume":"17","author":"Toma","year":"2000","journal-title":"Int J Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.002_bib75","first-page":"204","article-title":"Tamoxifen vs tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial","volume":"78","author":"Chiesa","year":"2007","journal-title":"Acta Biomed"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.002_bib76","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3892\/or_00000317","article-title":"Beta-interferon, retinoids and tamoxifen in metastatic breast cancer: long-term follow-up of a phase II study","volume":"21","author":"Recchia","year":"2009","journal-title":"Oncol Rep"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib77","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1200\/JCO.2003.05.068","article-title":"Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer","volume":"21","author":"Esteva","year":"2003","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1053\/j.seminoncol.2015.09.002_bib78","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1200\/JCO.2009.26.6452","article-title":"Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer","volume":"28","author":"Arrieta","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminoncol.2015.09.002_bib79","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1200\/JCO.2001.19.10.2626","article-title":"Multi-institutional phase I\/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer","volume":"19","author":"Khuri","year":"2001","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.002_bib80","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1200\/JCO.2007.12.2614","article-title":"Randomized phase III trial comparing bexarotene (L1069-49)\/cisplatin\/vinorelbine with cisplatin\/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I","volume":"26","author":"Ramlau","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.002_bib81","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/2159-8274.CD-10-0010","article-title":"The BATTLE trial: personalizing therapy for lung cancer","volume":"1","author":"Kim","year":"2011","journal-title":"Cancer Disc"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib82","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/1940-6207.CAPR-10-0376","article-title":"Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models","volume":"4","author":"Dragnev","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib83","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1158\/1078-0432.CCR-06-1836","article-title":"A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer","volume":"13","author":"Dragnev","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2015.09.002_bib84","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1749-6632.2001.tb02724.x","article-title":"Cyclin proteolysis as a retinoid cancer prevention mechanism","volume":"952","author":"Dragnev","year":"2001","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.002_bib85","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0090-9556(25)08302-3","article-title":"Kinetics of tissue distribution and elimination of retinoid drugs in the rat. II. Etretinate","volume":"22","author":"Eisenhardt","year":"1994","journal-title":"Drug Metabl Dispos"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.002_bib86","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2710.2008.00935.x","article-title":"Retinoic acid syndrome: a review","volume":"33","author":"Patatanian","year":"2008","journal-title":"Journal of clinical pharmacy and therapeutics"},{"issue":"6 Pt 2","key":"10.1053\/j.seminoncol.2015.09.002_bib87","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0190-9622(08)80257-5","article-title":"Long-term safety of retinoid therapy","volume":"27","author":"Vahlquist","year":"1992","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib88","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2133.2006.07329.x","article-title":"Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion","volume":"155","author":"Assaf","year":"2006","journal-title":"Br J Dermatol"},{"issue":"42","key":"10.1053\/j.seminoncol.2015.09.002_bib89","doi-asserted-by":"crossref","first-page":"35647","DOI":"10.1074\/jbc.M507924200","article-title":"Retinoid absorption and storage is impaired in mice lacking lecithin:retinol acyltransferase (LRAT)","volume":"280","author":"O\u05f3Byrne","year":"2005","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.002_bib90","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/ajmg.a.33038","article-title":"Pulmonary hypoplasia-diaphragmatic hernia-anophthalmia-cardiac defect (PDAC) syndrome due to STRA6 mutations\u2014what are the minimal criteria?","volume":"149A","author":"Segel","year":"2009","journal-title":"Am J Med Genet Part A."},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib91","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-4652(200011)185:2<302::AID-JCP15>3.0.CO;2-#","article-title":"Retinol conversion to retinoic acid is impaired in breast cancer cell lines relative to normal cells","volume":"185","author":"Mira","year":"2000","journal-title":"J Cell Physiol"},{"issue":"18","key":"10.1053\/j.seminoncol.2015.09.002_bib92","doi-asserted-by":"crossref","first-page":"8118","DOI":"10.1158\/0008-5472.CAN-04-4562","article-title":"The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer","volume":"65","author":"Kim","year":"2005","journal-title":"Cancer Res"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.002_bib93","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/onc.2009.414","article-title":"Oncogenic and cell survival properties of the retinoic acid metabolizing enzyme, CYP26A1","volume":"29","author":"Osanai","year":"2010","journal-title":"Oncogene"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib94","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1084\/jem.42.6.753","article-title":"Tissue changes following deprivation of fat-soluble a vitamin","volume":"42","author":"Wolbach","year":"1925","journal-title":"J Exp Med"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.002_bib95","first-page":"1379","article-title":"Effect of vitamin A deficiency on rat colon carcinogenesis by N-methyl-N\u05f3-nitro-N-nitrosoguanidine","volume":"36","author":"Narisawa","year":"1976","journal-title":"Cancer Res"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.002_bib96","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/ijc.2910170311","article-title":"The influence of vitamin A on the susceptibility of the rat lung to 3-methylcholanthrene","volume":"17","author":"Nettesheim","year":"1976","journal-title":"Int J Cancer"},{"issue":"20","key":"10.1053\/j.seminoncol.2015.09.002_bib97","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1158\/1078-0432.CCR-06-2681","article-title":"The rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice","volume":"13","author":"Li","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"7 Suppl","key":"10.1053\/j.seminoncol.2015.09.002_bib98","first-page":"2032s","article-title":"Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide","volume":"54","author":"Costa","year":"1994","journal-title":"Cancer Res"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.002_bib99","first-page":"153","article-title":"Evaluation of N-4-(hydroxycarbophenyl) retinamide as a cancer prevention agent and as a cancer chemotherapeutic agent","volume":"4","author":"Han","year":"1990","journal-title":"In Vivo"},{"issue":"38","key":"10.1053\/j.seminoncol.2015.09.002_bib100","doi-asserted-by":"crossref","first-page":"26783","DOI":"10.1074\/jbc.274.38.26783","article-title":"The targeted disruption of both alleles of RARbeta(2) in F9 cells results in the loss of retinoic acid-associated growth arrest","volume":"274","author":"Faria","year":"1999","journal-title":"J Biol Chem"},{"issue":"14","key":"10.1053\/j.seminoncol.2015.09.002_bib101","doi-asserted-by":"crossref","first-page":"6476","DOI":"10.1158\/0008-5472.CAN-05-0370","article-title":"Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms","volume":"65","author":"Ma","year":"2005","journal-title":"Cancer Res"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.002_bib102","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib103","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.3892\/ijo.2014.2354","article-title":"All trans-retinoic acid (ATRA) induces re-differentiation of early transformed breast epithelial cells","volume":"44","author":"Arisi","year":"2014","journal-title":"Int J Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib104","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrc2981","article-title":"Regulation of cancer cell metabolism","volume":"11","author":"Cairns","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib105","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","article-title":"Cellular fatty acid metabolism and cancer","volume":"18","author":"Currie","year":"2013","journal-title":"Cell metabolism"},{"issue":"10","key":"10.1053\/j.seminoncol.2015.09.002_bib106","first-page":"793","article-title":"RAR and RXR modulation in cancer and metabolic disease","volume":"6","author":"Altucci","year":"2007","journal-title":"Nat Rev"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.002_bib107","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/jcp.24601","article-title":"PPAR\u03b3 and RXR ligands disrupt the inflammatory cross-talk in the hypoxic breast cancer stem cells niche","volume":"229","author":"Papi","year":"2014","journal-title":"J Cell Physiol"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.002_bib108","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2159-8290.CD-11-0241","article-title":"Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women","volume":"2","author":"Subbaramaiah","year":"2012","journal-title":"Cancer Disc"},{"issue":"12","key":"10.1053\/j.seminoncol.2015.09.002_bib109","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1158\/1940-6207.CAPR-13-0182","article-title":"A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease","volume":"6","author":"Disis","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"issue":"9","key":"10.1053\/j.seminoncol.2015.09.002_bib110","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1158\/2159-8290.CD-12-0107","article-title":"CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues","volume":"2","author":"DeFilippis","year":"2012","journal-title":"Cancer Disc"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.002_bib111","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1593\/neo.121950","article-title":"Breast fibroblasts modulate early dissemination, tumorigenesis, and metastasis through alteration of extracellular matrix characteristics","volume":"15","author":"Dumont","year":"2013","journal-title":"Neoplasia"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib112","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ctrv.2014.01.001","article-title":"Retinoids and breast cancer: from basic studies to the clinic and back again","volume":"40","author":"Garattini","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.002_bib113","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3816\/CLC.2005.n.003","article-title":"Nonclassical retinoids and lung carcinogenesis","volume":"6","author":"Dragnev","year":"2005","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.002_bib114","first-page":"1339","article-title":"N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat","volume":"39","author":"Moon","year":"1979","journal-title":"Cancer Res"},{"issue":"9","key":"10.1053\/j.seminoncol.2015.09.002_bib115","first-page":"3696","article-title":"9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice","volume":"6","author":"Wu","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1053\/j.seminoncol.2015.09.002_bib116","first-page":"4614","article-title":"Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen","volume":"54","author":"Anzano","year":"1994","journal-title":"Cancer Res"},{"issue":"22","key":"10.1053\/j.seminoncol.2015.09.002_bib117","first-page":"6376","article-title":"The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice","volume":"62","author":"Wu","year":"2002","journal-title":"Cancer Res"},{"issue":"19","key":"10.1053\/j.seminoncol.2015.09.002_bib118","doi-asserted-by":"crossref","first-page":"5902","DOI":"10.1158\/1078-0432.CCR-06-1119","article-title":"The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer","volume":"12","author":"Liby","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1053\/j.seminoncol.2015.09.002_bib119","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1158\/1940-6207.CAPR-11-0524","article-title":"The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in p53-null mammary gland mice","volume":"5","author":"Mazumdar","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.002_bib120","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1158\/1940-6207.CAPR-08-0021","article-title":"Combination chemoprevention of HER2\/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid","volume":"1","author":"Brown","year":"2008","journal-title":"Cancer Prev Res (Phila)"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.002_bib121","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2009.04.043","article-title":"Genomic antagonism between retinoic acid and estrogen signaling in breast cancer","volume":"137","author":"Hua","year":"2009","journal-title":"Cell"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib122","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1593\/neo.111440","article-title":"Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min\/+) mice","volume":"14","author":"Janakiram","year":"2012","journal-title":"Neoplasia"},{"issue":"7291","key":"10.1053\/j.seminoncol.2015.09.002_bib123","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/nature08871","article-title":"Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis","volume":"464","author":"Zhang","year":"2010","journal-title":"Nature"},{"issue":"9","key":"10.1053\/j.seminoncol.2015.09.002_bib124","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/ijc.21618","article-title":"Prevention of mouse lung tumors by targretin","volume":"118","author":"Pereira","year":"2006","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.002_bib125","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1158\/1535-7163.MCT-08-0023","article-title":"The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis","volume":"7","author":"Liby","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.002_bib126","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s002800050582","article-title":"A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis","volume":"39","author":"Trump","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib127","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/carcin\/bgh093","article-title":"An acyclic retinoid, NIK-333, inhibits N-diethylnitrosamine-induced rat hepatocarcinogenesis through suppression of TGF-alpha expression and cell proliferation","volume":"25","author":"Kagawa","year":"2004","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.002_bib128","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1158\/1940-6207.CAPR-10-0163","article-title":"Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BLKS\/J- +(db)\/+Lepr(db) mice","volume":"4","author":"Shimizu","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1091581809360070","article-title":"Murine oncogenicity and pharmacokinetics studies of 9-cis-UAB30, an RXR agonist, for breast cancer chemoprevention","volume":"29","author":"Kapetanovic","year":"2010","journal-title":"Int J Toxicol"},{"issue":"10","key":"10.1053\/j.seminoncol.2015.09.002_bib130","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1158\/1078-0432.CCR-05-2636","article-title":"Fenretinide activity in retinoid-resistant oral leukoplakia","volume":"12","author":"Lippman","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.002_bib131","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/jnci\/djj091","article-title":"Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients","volume":"98","author":"Khuri","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.002_bib132","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archotol.131.3.198","article-title":"Chemoprevention of head and neck cancer with retinoids: a negative result","volume":"131","author":"Perry","year":"2005","journal-title":"Arch Otolaryngol"},{"issue":"13","key":"10.1053\/j.seminoncol.2015.09.002_bib133","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-11-3271","article-title":"Genetic variants in the PI3K\/PTEN\/AKT\/mTOR pathway predict head and neck cancer patient second primary tumor\/recurrence risk and response to retinoid chemoprevention","volume":"18","author":"Hildebrandt","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.002_bib134","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1124\/mol.63.3.565","article-title":"N-(4-hydroxyphenyl)retinamide inhibits retinoblastoma growth through reactive oxygen species-mediated cell death","volume":"63","author":"Tosetti","year":"2003","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib135","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1345\/aph.1R353","article-title":"Targeted immunotherapy for high-risk neuroblastoma\u2014the role of monoclonal antibodies","volume":"47","author":"Parsons","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.002_bib136","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/jnci\/95.3.206","article-title":"Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial","volume":"95","author":"Kurie","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.002_bib137","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1200\/JCO.2007.12.2689","article-title":"Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II","volume":"26","author":"Blumenschein","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.002_bib138","first-page":"3015","article-title":"Inhaled isotretinoin (13-cis retinoic acid) is an effective lung cancer chemopreventive agent in A\/J mice at low doses: a pilot study","volume":"6","author":"Dahl","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1053\/j.seminoncol.2015.09.002_bib139","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1940-6207.CAPR-09-0221","article-title":"Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer","volume":"2","author":"Wang","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib140","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/1940-6207.CAPR-10-0246","article-title":"Aerosolized bexarotene inhibits lung tumorigenesis without increasing plasma triglyceride and cholesterol levels in mice","volume":"4","author":"Zhang","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.002_bib141","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3945\/ajcn.2009.27568","article-title":"Longitudinal study of serum carotenoid, retinol, and tocopherol concentrations in relation to breast cancer risk among postmenopausal women","volume":"90","author":"Kabat","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"10.1053\/j.seminoncol.2015.09.002_bib142","doi-asserted-by":"crossref","first-page":"172897","DOI":"10.1155\/2012\/172897","article-title":"Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?","volume":"2012","author":"Cazzaniga","year":"2012","journal-title":"J Biomed Biotechnol"},{"issue":"21","key":"10.1053\/j.seminoncol.2015.09.002_bib143","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/jnci\/91.21.1847","article-title":"Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer","volume":"91","author":"Veronesi","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.002_bib144","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/annonc\/mdl047","article-title":"Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer","volume":"17","author":"Veronesi","year":"2006","journal-title":"Ann Oncol"},{"issue":"7 Suppl","key":"10.1053\/j.seminoncol.2015.09.002_bib145","article-title":"Abstract CN04-04: Phase II trial of bexarotene in women at high risk of breast cancer: Comparison of protein and RNA biomarkers","volume":"1","author":"Brown","year":"2008","journal-title":"Cancer Prev Res (Phila)"},{"issue":"13","key":"10.1053\/j.seminoncol.2015.09.002_bib146","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJM199904013401315","article-title":"Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma","volume":"340","author":"Muto","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.002_bib147","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000082093","article-title":"Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data","volume":"48","author":"Takai","year":"2005","journal-title":"Intervirology"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib148","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00535-014-0956-9","article-title":"Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study","volume":"50","author":"Okita","year":"2015","journal-title":"J Gastroenterol"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib149","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00535-014-0996-1","article-title":"Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial","volume":"50","author":"Okita","year":"2015","journal-title":"J Gastroenterology"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2515\/therapie:2007020","article-title":"Pharmacokinetics and pharmacogenetics of 13-cis-retinoic acid in the treatment of neuroblastoma","volume":"62","author":"Veal","year":"2007","journal-title":"Therapie"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.002_bib151","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/0091270007309701","article-title":"Pharmacokinetics and metabolism of all-trans- and 13-cis-retinoic acid in pulmonary emphysema patients","volume":"48","author":"Muindi","year":"2008","journal-title":"J Clin Pharmacol"},{"issue":"1-2","key":"10.1053\/j.seminoncol.2015.09.002_bib152","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/10428199709109156","article-title":"Tretinoin tocoferil as a possible differentiation-inducing agent against myelomonocytic leukemia","volume":"26","author":"Makishima","year":"1997","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.002_bib153","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1124\/mol.112.082404","article-title":"Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and Targretin (Bexarotene)","volume":"83","author":"Vedell","year":"2013","journal-title":"Mol Pharmacol"},{"issue":"12","key":"10.1053\/j.seminoncol.2015.09.002_bib154","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1158\/1940-6207.CAPR-10-0149","article-title":"A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers","volume":"3","author":"Kolesar","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.002_bib155","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1349-7006.2006.00384.x","article-title":"Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells","volume":"98","author":"Kanamori","year":"2007","journal-title":"Cancer sci"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib156","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/mol.111.072967","article-title":"Cancer-preventive rexinoid modulates neutral lipid contents of mammary epithelial cells through a peroxisome proliferator-activated receptor gamma-dependent mechanism","volume":"81","author":"Uray","year":"2012","journal-title":"Mol Pharmacol"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.002_bib157","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/jnci\/92.5.418","article-title":"A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions","volume":"92","author":"Mehta","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"10.1053\/j.seminoncol.2015.09.002_bib158","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: Challenges and Opportunities in Drug Discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J Med Chem"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib159","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/1940-6207.CAPR-11-0143","article-title":"Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy","volume":"4","author":"Kim","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"issue":"12","key":"10.1053\/j.seminoncol.2015.09.002_bib160","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/jamadermatol.2013.6746","article-title":"High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris","volume":"149","author":"Blasiak","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.002_bib161","first-page":"438","article-title":"The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies","volume":"12","author":"Feldman","year":"2013","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.002_bib162","first-page":"s53","article-title":"A status report on topical tazarotene in the management of acne vulgaris","volume":"12","author":"Del Rosso","year":"2013","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.002_bib163","first-page":"146","article-title":"A combined analysis of 2 randomized clinical studies of tretinoin gel 0.05% for the treatment of acne","volume":"83","author":"Webster","year":"2009","journal-title":"Cutis"},{"issue":"Suppl 3","key":"10.1053\/j.seminoncol.2015.09.002_bib164","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.0926-9959.2001.00008.x","article-title":"Pivotal clinical trials of adapalene in the treatment of acne","volume":"15","author":"Millikan","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.002_bib165","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000056361","article-title":"Retinoids\u2014which dermatological indications will benefit in the near future?","volume":"14","author":"Zouboulis","year":"2001","journal-title":"Skin Pharmacol Applied Skin Physiol"},{"issue":"9","key":"10.1053\/j.seminoncol.2015.09.002_bib166","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00403-006-0720-y","article-title":"MDI 301, a non-irritating retinoid, induces changes in human skin that underlie repair","volume":"298","author":"Varani","year":"2007","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib167","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jdiacomp.2011.10.002","article-title":"Effects of a synthetic retinoid on skin structure, matrix metalloproteinases, and procollagen in healthy and high-risk subjects with diabetes","volume":"25","author":"Zeng","year":"2011","journal-title":"J Diabetes Complications"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.002_bib168","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/1940-6207.CAPR-13-0305","article-title":"Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome","volume":"7","author":"Tang","year":"2014","journal-title":"Cancer Prev Res (Phila)"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib169","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2009.09037.x","article-title":"Bexarotene therapy for mycosis fungoides and Sezary syndrome","volume":"160","author":"Abbott","year":"2009","journal-title":"Br J Dermatol"},{"issue":"16","key":"10.1053\/j.seminoncol.2015.09.002_bib170","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1200\/JCO.2002.02.090","article-title":"Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer","volume":"20","author":"Rizvi","year":"2002","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminoncol.2015.09.002_bib171","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00432-008-0406-2","article-title":"A phase I\/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma","volume":"134","author":"Higginbotham","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib172","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1872-034X.2011.00800.x","article-title":"Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333","volume":"41","author":"Okusaka","year":"2011","journal-title":"Hepatol Res"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.002_bib173","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/j.1349-7006.2012.02334.x","article-title":"Phase I study of TAC-101, an oral synthetic retinoid, in Japanese patients with advanced hepatocellular carcinoma","volume":"103","author":"Okusaka","year":"2012","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.002_bib174","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/B:NEON.0000024748.26608.2f","article-title":"Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy--a phase-II study","volume":"68","author":"Wismeth","year":"2004","journal-title":"J Neurooncol"},{"issue":"12","key":"10.1053\/j.seminoncol.2015.09.002_bib175","first-page":"1931","article-title":"Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid","volume":"2","author":"Yung","year":"1996","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.002_bib176","first-page":"635","article-title":"Phase I\/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer","volume":"4","author":"Budd","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.002_bib177","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0145-2126(89)90071-4","article-title":"Phase II trial of fenretinide [N-(4-hydroxyphenyl) retinamide] in myelodysplasia: possible retinoid-induced disease acceleration","volume":"13","author":"Garewal","year":"1989","journal-title":"Leuk Res"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.002_bib178","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00280-003-0644-6","article-title":"A phase I trial of weekly paclitaxel, 13- cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies","volume":"52","author":"Thalasila","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2015.09.002_bib179","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1479-5876-8-20","article-title":"A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899","volume":"8","author":"DiPaola","year":"2010","journal-title":"J Translat Med"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib180","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0959-8049(94)90290-9","article-title":"Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study","volume":"30A","author":"Bolla","year":"1994","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.002_bib181","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2001.19.6.1664","article-title":"Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer","volume":"19","author":"Camerini","year":"2001","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.002_bib182","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/1940-6207.CAPR-08-0136","article-title":"A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer","volume":"2","author":"Kelly","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"issue":"23","key":"10.1053\/j.seminoncol.2015.09.002_bib183","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/jnci\/86.23.1799-a","article-title":"Toxicity of isotretinoin in a chemoprevention trial to prevent second primary tumors following head and neck cancer","volume":"86","author":"Benner","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.002_bib184","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.2008.17.1850","article-title":"Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy","volume":"27","author":"Papadimitrakopoulou","year":"2009","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1053\/j.seminoncol.2015.09.002_bib185","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM199606133342402","article-title":"Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group","volume":"334","author":"Muto","year":"1996","journal-title":"N Engl J Med"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775415001670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775415001670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T20:34:54Z","timestamp":1748637294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775415001670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":185,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0093775415001670"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2015.09.002","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}